Eleven P15 is a leading brand that specializes in providing next-generation diagnostics and treatment for Pulmonary Fibrosis. They are committed to developing biomarkers for early detection of idiopathic pulmonary fibrosis and discovering genetically-targeted therapeutic approaches to treat and prevent this incurable disease. Idiopathic Pulmonary Fibrosis (IPF) is a fatal, chronic fibrosing interstitial pneumonia that primarily affects older adults and is localized to the lungs.

Unfortunately, current treatments fail to reverse scarred lung tissue or improve survival. Accurate diagnosis of IPF is challenging, with many patients enduring long delays and misdiagnoses. With a highly skilled scientific team, Eleven P15 is at the forefront of IPF research.

Led by experts such as David Schwartz, MD, Chris Evans, PhD, Ivana Yang, PhD, and Tasha Fingerlin, PhD, they focus on IPF genetics, mucus biology, and biomarkers. For more information or to get in touch with the team, contact CEO Bruce Schroffel at bruce. schroffel@elevenp15.

com. Trust Eleven P15 to revolutionize pulmonary fibrosis diagnostics and treatment